title: Surface-modified amikacin-liposomes: organ distribution and interaction with plasma proteins.
abstract: Amikacin-loaded liposomes were produced and surface-modified by adsorption of PEG 4000, Tween 80, poloxamer 407 and gelatin. The organ distribution was studied in mice by analysing the amikacin content in liver, spleen, lung, kidneys and serum. Highest serum levels were obtained with the PEG- and Tween 80 modified liposomes (at 2 hours p.inj.). Modification of the liposomes with gelatin as opsonization promoting agent distinctly increased the amikacin concentration in the liver from 36 to 66 mg/kg. Highest spleen concentrations were observed with non-modified and poloxamer 407 liposomes (242 mg/kg and 248 mg/kg, respectively). The data suggest that modification by a simple adsorption process is sufficient to effectively alter the organ distribution. The liposomes differing in organ distribution exhibited also different plasma protein adsorption patterns, up to 115 spots were detected by 2-D PAGE. Hydrophilic albumin was present in a conc. of appr. 80% on liposomes modified with ethoxylated compounds. On the gelatin liposomes, 14% of alpha-2-Macroglobulin were adsorbed which is a protein typically found on particles rapidly cleared by the RES. IgM, Apo A-I, Apo C-II and alpha-1-Antitrypsin were other detected proteins.
authors.affiliation: The Free University of Berlin, Department of Pharmaceutics, Biopharmaceutics & Biotechnology, Germany.
authors.forename: W E
authors.initials: WE
authors.lastname: Bucke
authors.forename: S
authors.initials: S
authors.lastname: Leitzke
authors.forename: J E
authors.initials: JE
authors.lastname: Diederichs
authors.forename: K
authors.initials: K
authors.lastname: Borner
authors.forename: H
authors.initials: H
authors.lastname: Hahn
authors.forename: S
authors.initials: S
authors.lastname: Ehlers
authors.forename: R H
authors.initials: RH
authors.lastname: Müller
mesh_terms: D000583:Amikacin / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics*; D001798:Blood Proteins / Q000378:metabolism*; D005260:Female; D007275:Injections, Intravenous; D008081:Liposomes; D051379:Mice; D008810:Mice, Inbred C57BL; D011108:Polymers; D011485:Protein Binding; D014018:Tissue Distribution
chemical_list: D000900:Anti-Bacterial Agents; D001798:Blood Proteins; D008081:Liposomes; D011108:Polymers; D000583:Amikacin